How much did Zelira Therapeutics achieve in EBIT for the current year?
In the current year, Zelira Therapeutics has achieved an EBIT of 19 M AUD.
Zelira Therapeutics EBIT 2025
Zelira Therapeutics EBIT
19 M AUD
Ticker
ZLD.AX
ISIN
AU000000ZLD1
WKN
A2AS5H
In 2025, Zelira Therapeutics's EBIT was 19 M AUD, a -479.32% increase from the -5.01 M AUD EBIT recorded in the previous year.
The Zelira Therapeutics EBIT history
| YEAR | EBIT (undefined AUD) |
|---|---|
| 2026e | -2.83 |
| 2025e | 19 |
| 2024 | -5.01 |
| 2023 | -5.87 |
| 2022 | -11.7 |
| 2021 | -7.86 |
| 2020 | -6.9 |
| 2019 | -3.38 |
| 2018 | -2.27 |
| 2017 | -2.44 |
| 2016 | -0.4 |
| 2015 | -0.41 |
| 2014 | -0.27 |
| 2013 | -0.29 |
| 2012 | -0.6 |
| 2011 | 0.04 |
| 2010 | -1 |
| 2009 | -1 |
| 2008 | -0.27 |
| 2007 | -17.36 |
| 2006 | -3.98 |
| 2005 | -0.3 |
Zelira Therapeutics Revenue, EBIT, Net Income AU000000ZLD1 · A2AS5H
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Zelira Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zelira Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zelira Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Zelira Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Zelira Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Zelira Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zelira Therapeutics’s growth potential.
Zelira Therapeutics Revenue, EBIT and net profit per share
| Date | Zelira Therapeutics Revenue | Zelira Therapeutics EBIT | Zelira Therapeutics Net Income |
|---|---|---|---|
| 2026e | 24.9 B undefined | -2.83 M undefined | -5.06 M undefined |
| 2025e | 46.54 M undefined | 19 M undefined | 11,463.5 undefined |
| 2024 | 95,260 undefined | -5.01 M undefined | -36.57 M undefined |
| 2023 | 551,260 undefined | -5.87 M undefined | -5.57 M undefined |
| 2022 | 2.89 M undefined | -11.7 M undefined | -11.95 M undefined |
| 2021 | 2.09 M undefined | -7.86 M undefined | -8.55 M undefined |
| 2020 | 1.04 M undefined | -6.9 M undefined | -7.02 M undefined |
| 2019 | 859,170 undefined | -3.38 M undefined | -3.57 M undefined |
| 2018 | 561,390 undefined | -2.27 M undefined | -1.73 M undefined |
| 2017 | 167,760 undefined | -2.44 M undefined | -6.16 M undefined |
| 2016 | 2,730 undefined | -397,580 undefined | -898,640 undefined |
| 2015 | 11,590 undefined | -412,240 undefined | -400,080 undefined |
| 2014 | 20,000 undefined | -270,000 undefined | -290,000 undefined |
| 2013 | 30,000 undefined | -290,000 undefined | -310,000 undefined |
| 2012 | 30,000 undefined | -600,000 undefined | -640,000 undefined |
| 2011 | 500,000 undefined | 40,000 undefined | 10,000 undefined |
| 2010 | 160,000 undefined | -1 M undefined | -1.69 M undefined |
| 2009 | 130,000 undefined | -1 M undefined | -20.27 M undefined |
| 2008 | 20,000 undefined | -270,000 undefined | 12.61 M undefined |
| 2007 | 21.15 M undefined | -17.36 M undefined | -38.16 M undefined |
| 2006 | 240,000 undefined | -3.98 M undefined | -900,000 undefined |
| 2005 | 730,000 undefined | -300,000 undefined | -310,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 730,000 AUD | -300,000 AUD | -310,000 AUD |
| 2006 | 240,000 AUD | -3.98 M AUD | -900,000 AUD |
| 2007 | 21.15 M AUD | -17.36 M AUD | -38.16 M AUD |
| 2008 | 20,000 AUD | -270,000 AUD | 12.61 M AUD |
| 2009 | 130,000 AUD | -1 M AUD | -20.27 M AUD |
| 2010 | 160,000 AUD | -1 M AUD | -1.69 M AUD |
| 2011 | 500,000 AUD | 40,000 AUD | 10,000 AUD |
| 2012 | 30,000 AUD | -600,000 AUD | -640,000 AUD |
| 2013 | 30,000 AUD | -290,000 AUD | -310,000 AUD |
| 2014 | 20,000 AUD | -270,000 AUD | -290,000 AUD |
| 2015 | 11,590 AUD | -412,240 AUD | -400,080 AUD |
| 2016 | 2,730 AUD | -397,580 AUD | -898,640 AUD |
| 2017 | 167,760 AUD | -2.44 M AUD | -6.16 M AUD |
| 2018 | 561,390 AUD | -2.27 M AUD | -1.73 M AUD |
| 2019 | 859,170 AUD | -3.38 M AUD | -3.57 M AUD |
| 2020 | 1.04 M AUD | -6.9 M AUD | -7.02 M AUD |
| 2021 | 2.09 M AUD | -7.86 M AUD | -8.55 M AUD |
| 2022 | 2.89 M AUD | -11.7 M AUD | -11.95 M AUD |
| 2023 | 551,260 AUD | -5.87 M AUD | -5.57 M AUD |
| 2024 | 95,260 AUD | -5.01 M AUD | -36.57 M AUD |
| 2025e | 46.54 M AUD | 19 M AUD | 11,463.5 AUD |
| 2026e | 24.9 B AUD | -2.83 M AUD | -5.06 M AUD |
Zelira Therapeutics stock margins AU000000ZLD1 · A2AS5H
The Zelira Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zelira Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zelira Therapeutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Zelira Therapeutics's sales revenue. A higher gross margin percentage indicates that the Zelira Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Zelira Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Zelira Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zelira Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zelira Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zelira Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Zelira Therapeutics Margin History
| Zelira Therapeutics Gross margin | Zelira Therapeutics Profit margin | Zelira Therapeutics EBIT margin | Zelira Therapeutics Profit margin |
|---|---|---|---|
| 2026e | 11.12 % | -0.01 % | -0.02 % |
| 2025e | 11.12 % | 40.83 % | 0.02 % |
| 2024 | 11.12 % | -5,258.43 % | -38,388.52 % |
| 2023 | 34.23 % | -1,064.87 % | -1,010.96 % |
| 2022 | 67.55 % | -404.5 % | -412.84 % |
| 2021 | 89.09 % | -375.51 % | -408.58 % |
| 2020 | 11.12 % | -662.87 % | -674.28 % |
| 2019 | 11.12 % | -393.31 % | -415.26 % |
| 2018 | 11.12 % | -403.79 % | -308.13 % |
| 2017 | 11.12 % | -1,453.54 % | -3,670.37 % |
| 2016 | 11.12 % | -14,563.37 % | -32,917.22 % |
| 2015 | 11.12 % | -3,556.86 % | -3,451.94 % |
| 2014 | 11.12 % | -1,350 % | -1,450 % |
| 2013 | 11.12 % | -966.67 % | -1,033.33 % |
| 2012 | 11.12 % | -2,000 % | -2,133.33 % |
| 2011 | 11.12 % | 8 % | 2 % |
| 2010 | 11.12 % | -625 % | -1,056.25 % |
| 2009 | 11.12 % | -769.23 % | -15,592.31 % |
| 2008 | 100 % | -1,350 % | 63,050 % |
| 2007 | 27.28 % | -82.08 % | -180.43 % |
| 2006 | 100 % | -1,658.33 % | -375 % |
| 2005 | 11.12 % | -41.1 % | -42.47 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 11.12 % | -41.1 % | -42.47 % |
| 2006 | 100 % | -1,658.33 % | -375 % |
| 2007 | 27.28 % | -82.08 % | -180.43 % |
| 2008 | 100 % | -1,350 % | 63,050 % |
| 2009 | 11.12 % | -769.23 % | -15,592.31 % |
| 2010 | 11.12 % | -625 % | -1,056.25 % |
| 2011 | 11.12 % | 8 % | 2 % |
| 2012 | 11.12 % | -2,000 % | -2,133.33 % |
| 2013 | 11.12 % | -966.67 % | -1,033.33 % |
| 2014 | 11.12 % | -1,350 % | -1,450 % |
| 2015 | 11.12 % | -3,556.86 % | -3,451.94 % |
| 2016 | 11.12 % | -14,563.37 % | -32,917.22 % |
| 2017 | 11.12 % | -1,453.54 % | -3,670.37 % |
| 2018 | 11.12 % | -403.79 % | -308.13 % |
| 2019 | 11.12 % | -393.31 % | -415.26 % |
| 2020 | 11.12 % | -662.87 % | -674.28 % |
| 2021 | 89.09 % | -375.51 % | -408.58 % |
| 2022 | 67.55 % | -404.5 % | -412.84 % |
| 2023 | 34.23 % | -1,064.87 % | -1,010.96 % |
| 2024 | 11.12 % | -5,258.43 % | -38,388.52 % |
| 2025e | 11.12 % | 40.83 % | 0.02 % |
| 2026e | 11.12 % | -0.01 % | -0.02 % |
Zelira Therapeutics Aktienanalyse
What does Zelira Therapeutics do?
Zelira Therapeutics was founded in 2016 with its headquarters in Perth, Australia. The company focuses on the development, production, and marketing of medical cannabis to meet the needs of patients worldwide. The company's business model is based on producing medical cannabis specifically tailored to patients' needs. It works closely with doctors and patients to ensure its products are effective and meet patients' needs. Zelira Therapeutics operates in three main areas. The first is the development of products for treating pain and inflammation in chronic conditions such as multiple sclerosis, cancer, and epilepsy. The second area includes the development of products for treating sleep disorders. The third area is the development of products for treating mental disorders such as anxiety and depression. The company has developed a wide range of products, including oils, pills, sprays, and topical creams. An example of a product is the ZTL-101 oil, which was developed for treating pain and inflammation in patients with osteoarthritis. The oil contains a combination of CBD and THC. The company has also partnered with the University of Mississippi to research the use of medical cannabis for treating post-traumatic stress disorder (PTSD). The research is funded by the US government and aims to legitimize the use of medical cannabis for treating PTSD. Zelira Therapeutics has also formed partnerships with other companies and organizations to advance its research and development. In 2020, the company entered into an agreement with Emerald Health Therapeutics, a Canadian company specializing in the production of medical cannabis. The two companies will collaborate on developing products for treating sleep disorders. The company has also partnered with iCAN Israel-Cannabis, an Israel-based company specializing in the research and development of medical cannabis. The two companies are working together to develop new products and promote the use of medical cannabis in various countries. In addition to its partnerships, Zelira Therapeutics has established a strong presence in various international markets. It is currently operating in the US, Australia, New Zealand, and Germany, and is working to expand into other countries. Overall, Zelira Therapeutics is a company specializing in the development of medical cannabis for treating various conditions. It has a wide range of products and works closely with doctors and patients to ensure their effectiveness and meet patients' needs. With strong partnerships and a presence in various international markets, the company has a promising future. Zelira Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Zelira Therapeutics's EBIT
Zelira Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Zelira Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Zelira Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Zelira Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Zelira Therapeutics stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Zelira Therapeutics.
How has the EBIT of Zelira Therapeutics developed in recent years?
The EBIT of Zelira Therapeutics has increased by -479.324% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Zelira Therapeutics?
The EBIT of Zelira Therapeutics is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Zelira Therapeutics pay?
Over the past 12 months, Zelira Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zelira Therapeutics is expected to pay a dividend of 0 AUD.
What is the dividend yield of Zelira Therapeutics?
The current dividend yield of Zelira Therapeutics is .
When does Zelira Therapeutics pay dividends?
Zelira Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Zelira Therapeutics?
Zelira Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Zelira Therapeutics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Zelira Therapeutics located?
Zelira Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zelira Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zelira Therapeutics from 1/22/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 1/22/2025.
When did Zelira Therapeutics pay the last dividend?
The last dividend was paid out on 1/22/2025.
What was the dividend of Zelira Therapeutics in the year 2024?
In the year 2024, Zelira Therapeutics distributed 0 AUD as dividends.
In which currency does Zelira Therapeutics pay out the dividend?
The dividends of Zelira Therapeutics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Zelira Therapeutics
Our stock analysis for Zelira Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zelira Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Zelira Therapeutics Revenue
- Zelira Therapeutics Net Income
- Zelira Therapeutics P/E
- Zelira Therapeutics P/S
- Zelira Therapeutics EBIT
- Zelira Therapeutics Dividend
- Zelira Therapeutics Stocks
- Zelira Therapeutics Market capitalization
- Zelira Therapeutics Debt
- Zelira Therapeutics Liabilities
- Zelira Therapeutics Equity
- Zelira Therapeutics AAQS
- Zelira Therapeutics Employees
- Zelira Therapeutics ROE
- Zelira Therapeutics ROA
- Zelira Therapeutics ROCE
